Spinal Muscular Atrophy Type INCT06632730
Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain
An observational study of Spinal Muscular Atrophy Type I and Spinal Muscular Atrophy Type II, run by Novartis at 1 site in United States.
Trial summary
An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals). Read more about this study
- Who is it for?
- Ages Up to 14 years
- Conditions the study is for
- Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
- How many people
- 69 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Jul 2023to 20 Nov 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 14 years
- All sexes
- No healthy volunteers
- Child
Study population: This was a retrospective, noninterventional cohort study.
Who may be able to join
- Patients diagnosed with SMA type I or SMA type II.
- Patients with medical records available in the hospital.
- Patients diagnosed with SMA type I or SMA type II after 2017 for whom a minimum of 6 months of follow-up was available.
Who cannot join
- Patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.
Trial locations and contacts
1 site in 1 country.
United States1 site
Novartis Pharmaceuticals
East Hanover, New Jersey, 07936
About this study
Official title: Therapeutic Management and Current Situation Related to the Use of Resources and Costs of Spinal Muscular Atrophy (SMA) in Spain: A Retrospective, Multicenter Analysis Based on Medical Record Review. TREaSURE Study
An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).
- Medical subject headings
- Spinal Muscular Atrophies of Childhood
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Spinal Muscular Atrophy (SMA) Cohort | Pediatric patients with SMA type I, SMA type II, or presymptomatic SMA. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cost per Year of Use of Resources for Medical Visits
Medical visits included:
- Primary care
- Pediatric neurology
- Rehabilitation physician
- Traumatologist
- Nutritionist
- Pulmonologist
- Cardiologist
- Physical therapist
- Nursing staff
- Phoniatrist
- Speech therapist
- Rehabilitation sessions
- Other specialists
- Total medical visits
- Hospital emergency room visits
- Outpatient emergency room visit
- Hospitalizations/Admissions to ward
- Hospitalizations due to admissions to the intensive care unit (ICU)
- Total hospitalizations (ward and ICU)
- Therapy session separately from medical visits
Measured: Up to 12 months
Costs per Year of Use of Resources for Medical Tests
Medical tests included:
- Blood count
- Vitamin D test
- Blood creatine kinase test
- Electromyogram
- Brain magnetic resonance imaging
- Muscle magnetic resonance imaging
- Bone densitometry
- Nocturnal polysomnography
- Muscle biopsy
- Nerve conduction velocity study
- Blood amino acid test
- DNA test to confirm diagnosis
- Total additional tests
Measured: Up to 12 months
Cost per Year of Use of Resources for Treatment
Treatments included:
- Nusinersen (loading and maintenance dose)
- Total Nusinersen
- Risdiplam
- Onasemnogene abeparvovec
- Total treatments for SMA
- Palivizumab
- Influenza vaccine
- Meningococcal vaccine
- High protein shakes
- Total adjuvant treatments
- Total treatments
Measured: Up to 12 months
Secondary outcomes (46)
Number of Patients per Sociodemographic Category
Sociodemographics included:
- Biological sex
- Dead patients
- Growth percentiles for growth charts (3%, 4-15%, 16-50%, 51-85%, 86-97%, greater than 97%)
- Patient's cohabitants (father, mother, both parents, brother(s), sister(s), other relatives)
- Patient's caregiver (father, mother, both parents, brother(s), sister(s), other relatives)
- Patient's primary caregiver (father, mother, both parents, brother(s), sister(s), other relatives)
Measured: Baseline
Sociodemographic: Age
- Age at the time of data collection
- Age of onset of SMA symptoms
- Age at clinical diagnosis of SMA
- Age of death
Measured: Baseline
Sociodemographic: Weight
Measured: Baseline
Sociodemographic: Height
Measured: Baseline
Sociodemographic: Body mass index (BMI)
Measured: Baseline
Number of Patients per Clinical Characteristic Category
Clinical characteristics included:
- Anti-adeno-associated virus serotype 9 (AAV9) antibody titer test
- Neonatal screening for SMA together with other screening tests
- Prenatal or perinatal SMA diagnosis
- Ventilatory support
- Patient with scoliosis
- Patient with scoliosis surgery
- Patients with a chair for scoliosis
- Total or partial cost of the chair for scoliosis borne by the family
- Patients still use a chair for scoliosis at the time of data collection
- Patients with back brace
- Total or partial cost of the back brace borne by the family
- Patient with hip dislocations or subluxations
- Head control
- Relevant medical record
- End of ventilatory support
Measured: Baseline
Clinical Characteristic: Age From Which Information Was Available
Measured: Baseline
Clinical Characteristic: Time From Onset of Symptoms to Diagnosis
Time intervals included:
- Less than 1 month
- 1 to 3 months
- 4 to 6 months
- 7 to 18 months
- More than 18 months
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by International Classification of Diseases (ICD) Code
ICD codes included:
- ICD-9 335.1: Spinal muscular atrophy
- ICD-9: 335.1: Spinal muscular amyotrophy, unspecified
- ICD-9 335.11: Kugelberg-Welander disease
- ICD-10 G12.1: Other hereditary spinal muscular atrophies
- ICD-10 G12.25: Progressive spinal muscular atrophy
- ICD-10 G12.8: Other spinal muscular atrophies and related syndromes
- ICD-10 G12.9: Spinal muscular atrophy, unspecified
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Diagnosis of Muscle Atrophy
Diagnosis types included:
- Clinical suspicion and subsequent patient referral for genetic confirmation
- Genetic diagnosis
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Mutation
Mutations included:
- Biallelic deletion of exons
- Biallelic deletion of exon 7
- Biallelic deletion of exons 7 and 8
- Compound heterozygous mutation
- Point mutation and deletion of exons 7 and 8
- Biallelic point mutation
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Survival of Motor Neuron 2 (SMN2) Gene Copy Number
SMN2 copy numbers: 0, 1, 2, 3, 4, and greater than 4.
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by SMA-associated Comorbidities
SMA-associated comorbidities included:
- Chronic lung disease
- Swallowing impairment
- Malnutrition
- Hypoxic encephalopathy
- Relapsing obstructive bronchial syndrome
- Recurrent pneumonia
- Sleep apnea-hypopnea syndrome
- Epilepsy
- Hip dysplasia
- Obesity
- Respiratory compromise
- Thorax deformity
- Scoliosis
- Other
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Family History of SMA
Family history categories included:
- Yes
- No
- Mother
- Father
- Both parents
- Brothers and sisters
- Other
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Ventilatory Support
Types of ventilatory support included:
- Invasive (hospital and outpatient)
- Non-invasive (hospital and outpatient)
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Reason of Ventilatory Support Regimen
Reasons of ventilatory support included:
- Preventive intent
- Therapeutic intent
Measured: Baseline
Clinical Characteristic: Duration of Ventilatory Support
Measured: Baseline
Clinical Characteristic: Number of Patients With Nutritional Supplementation
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Administration of Nutritional Supplementation
Types of administration included:
- By mouth
- Through a feeding tube
- Both (mouth and feeding tube)
- Through gastrostomy
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Nutritional Supplementation Received by Mouth
Types of nutritional supplementation included liquid thickeners (corn starch and Nutilis Clear thickener, neutral taste, Nutricia) and nutrition supplements (Resource shakes, High protein shakes, Ensure Junior drink, Infatrini, Pediasure Complete, RESOURCE C, Vitamin D, Fortini high protein shakes, protein shakes, Pediasure, Resource with fiber, Resource protein).
Measured: Baseline
Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements by Mouth
Measured: Baseline
Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements Through a Feeding Tube
Measured: Baseline
Clinical Characteristic: Duration of Nutritional Supplementation Received by Mouth and Through a Feeding Tube or Gastrostomy
Measured: Baseline
Clinical Characteristic: Number of Surgeries for Patients With Scoliosis
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Surgery Received for Scoliosis
Types of surgeries included:
- Growing rods lengthening
- Dorsal/lumbar dorsal arthrodesis
- Growing rods
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Joint Contracture
Types of joint contractures included proximal and distal.
Measured: Baseline
Clinical Characteristic: Number of Patients Who Reached Each Motor Development Milestone
Developmental Milestones:
- Sitting independently or with support
- Standing independently or with support
- Walking independently or with support
- Crawling with the elbows, belly crawl, or with hands and knees
Measured: Baseline
Clinical Characteristic: Number of Patients Categorized by Relevant Surgical History in Addition to Scoliosis Surgery Related to SMA Categorized by Type of Surgery
Surgeries included:
- Mouth surgery
- Tracheostomy
- Surgery for gastrostomy
- Tenotomy
- Other
Measured: Baseline
Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year
Healthcare visits included:
- General
- Primary care
- Pediatric neurology
- Rehabilitation physician
- Traumatologist
- Nutritionist
- Pulmonology
- Cardiologist
- Physical therapy
- Nursing staff
- Phoniatrist
- Speech therapist
- Rehabilitation sessions
- Other experts
- Emergency Room
- Related to therapy
Measured: Up to 12 months
Total Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year
Measured: Up to 12 months
Number of Scheduled and Unscheduled SMA-related Medical Visits
SMA-related medical visits included:
- Primary care
- Pediatric neurology
- Rehabilitation physician
- Traumatologist
- Nutritionist
- Pulmonologist
- Cardiologist
- Physical therapist
- Nursing staff
- Phoniatrist
- Speech therapist
- Rehabilitation sessions
- Other specialists
Measured: Up to 12 months
Number of SMA-related Emergency Room Visits
SMA-related emergency room visits included outpatient and hospital visits.
Measured: Up to 12 months
Number of SMA-related Hospitalizations
SMA-related hospitalizations included visits to day hospital, admissions to ward, intensive care unit admissions.
Measured: Up to 12 months
Number of Patients Categorized by Reason for Hospitalization
Hospitalization included admission to ward. Reason for hospitalization included related to treatment and not related to treatment.
Measured: Up to 12 months
Number of Patients Categorized by Reason for Admission to Intensive Care Unit (ICU)
Reason for admission to ICU included related to treatment and not related to treatment.
Measured: Up to 12 months
Number of Patients With a Multidisciplinary Follow-up
Measured: Up to 12 months
Number of Patients Categorized by Medical Areas Involved in Follow-up
Medical areas included:
- Pulmonology
- Endocrinology/nutrition
- Physical therapy
- Rehabilitation
- Logopedics
- Thoracic surgery
- Orthopedics
- Other
Measured: Up to 12 months
Number of Patients Categorized by Type of Additional Tests Needed
Additional tests included:
- Blood count
- Vitamin D test
- Blood creatine kinase test
- Electromyogram
- Brain magnetic resonance imaging
- Muscle magnetic resonance imaging
- Bone densitometry
- Nocturnal polysomnography
- Muscle biopsy
- Nerve conduction velocity study
- Blood amino acid test
- DNA test to confirm diagnosis
Measured: Up to 12 months
Number of Times Each Additional Test Was Performed
Additional tests included:
- Blood count
- Vitamin D
- Blood creatine kinase
- Electromyogram
- Brain magnetic resonance imaging
- Muscle magnetic resonance imaging
- Bone densitometry
- Nocturnal polysomnography
- Muscle biopsy
- Nerve conduction velocity study
- Blood amino acid test
- DNA test to confirm diagnosis
Measured: Up to 12 months
Total Additional Tests
Measured: Up to 12 months
Number of Patients Categorized by Type of Treatment for SMA
Treatments included:
- Nusinersen
- Risdiplam
- Onasemnogene abeparvovec
- Palivizumab
- Influenza vaccine
- Meningococcal vaccine
- High protein shakes
Measured: Up to 6 years and 4 months
Number of Nusinersen Doses
Nusinersen doses included loading and maintenance doses.
Measured: Up to 6 years and 4 months
Risdiplam Dose
Risdiplam dose included starting dose and dose changes.
Measured: Up to 6 years and 4 months
Palivizumab Dose
Measured: Up to 6 years and 4 months
Number of High Protein Shakes per Day
Measured: Up to 6 years and 4 months
Number of Months of Taking High Protein Shakes
Measured: Up to 6 years and 4 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2024
- Study start5 Jul 2023
- Primary completion20 Nov 2023
- Study completion20 Nov 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Spinal Muscular Atrophy Type IStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 69 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Novartis Pharmaceuticals, Study director, Novartis Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06632730
- Sponsor's protocol ID
- COAV101A1ES05
- Status last verified
- Oct 2024
- First submitted
- 7 Oct 2024
- Last updated
- 9 Oct 2024
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Therapeutic Management and Current Situation Related to the Use of Resources and Costs of Spinal Muscular Atrophy (SMA) in Spain: A Retrospective, Multicenter Analysis Based on Medical Record Review. TREaSURE Study
- ClinicalTrials.gov ID
- NCT06632730
- Acronym / sponsor ID
- COAV101A1ES05
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 69 participants (actual)
- Lead sponsor
- NovartisIndustry (pharma, biotech, devices)
- Study start
- 5 Jul 2023 (actual)
- Primary completion
- 20 Nov 2023 (actual)
- Study completion
- 20 Nov 2023 (actual)
- First posted
- 9 Oct 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An observational, retrospective, cross-sectional, multicenter study. Real-world data were obtained from medical records of Spanish public hospitals (9 hospitals).
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Spinal Muscular Atrophy (SMA) Cohort | – | –Pediatric patients with SMA type I, SMA type II, or presymptomatic SMA. |
Who may qualify
- Ages
- Up to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- This was a retrospective, noninterventional cohort study.
Key inclusion criteria (3 listed)
- Patients diagnosed with SMA type I or SMA type II.
- Patients with medical records available in the hospital.
- Patients diagnosed with SMA type I or SMA type II after 2017 for whom a minimum of 6 months of follow-up was available.
Key exclusion criteria (1 listed)
- Patients who participated in an experimental design study except for those in the long-term follow-up period, during the observation period.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cost per Year of Use of Resources for Medical Visits
Time frame: Up to 12 months
Medical visits included: * Primary care * Pediatric neurology * Rehabilitation physician * Traumatologist * Nutritionist * Pulmonologist * Cardiologist * Physical therapist * Nursing staff * Phoniatrist * Speech therapist * Rehabilitation sessions * Other specialists * Total medical visits * Hospital emergency room visits * Outpatient emergency room visit * Hospitalizations/Admissions to ward * Hospitalizations due to admissions to the intensive care unit (ICU) * Total hospitalizations (ward and ICU) * Therapy session separately from medical visits
Costs per Year of Use of Resources for Medical Tests
Time frame: Up to 12 months
Medical tests included: * Blood count * Vitamin D test * Blood creatine kinase test * Electromyogram * Brain magnetic resonance imaging * Muscle magnetic resonance imaging * Bone densitometry * Nocturnal polysomnography * Muscle biopsy * Nerve conduction velocity study * Blood amino acid test * DNA test to confirm diagnosis * Total additional tests
Cost per Year of Use of Resources for Treatment
Time frame: Up to 12 months
Treatments included: * Nusinersen (loading and maintenance dose) * Total Nusinersen * Risdiplam * Onasemnogene abeparvovec * Total treatments for SMA * Palivizumab * Influenza vaccine * Meningococcal vaccine * High protein shakes * Total adjuvant treatments * Total treatments
46 secondary outcomes
Number of Patients per Sociodemographic Category
Time frame: Baseline
Sociodemographic: Age
Time frame: Baseline
Sociodemographic: Weight
Time frame: Baseline
Sociodemographic: Height
Time frame: Baseline
Sociodemographic: Body mass index (BMI)
Time frame: Baseline
Number of Patients per Clinical Characteristic Category
Time frame: Baseline
Clinical Characteristic: Age From Which Information Was Available
Time frame: Baseline
Clinical Characteristic: Time From Onset of Symptoms to Diagnosis
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by International Classification of Diseases (ICD) Code
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Diagnosis of Muscle Atrophy
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Mutation
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Survival of Motor Neuron 2 (SMN2) Gene Copy Number
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by SMA-associated Comorbidities
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Family History of SMA
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Ventilatory Support
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Reason of Ventilatory Support Regimen
Time frame: Baseline
Clinical Characteristic: Duration of Ventilatory Support
Time frame: Baseline
Clinical Characteristic: Number of Patients With Nutritional Supplementation
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Administration of Nutritional Supplementation
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Nutritional Supplementation Received by Mouth
Time frame: Baseline
Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements by Mouth
Time frame: Baseline
Clinical Characteristic: Number of Patients Who Received Liquid Thickener and Nutritional Supplements Through a Feeding Tube
Time frame: Baseline
Clinical Characteristic: Duration of Nutritional Supplementation Received by Mouth and Through a Feeding Tube or Gastrostomy
Time frame: Baseline
Clinical Characteristic: Number of Surgeries for Patients With Scoliosis
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Surgery Received for Scoliosis
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Type of Joint Contracture
Time frame: Baseline
Clinical Characteristic: Number of Patients Who Reached Each Motor Development Milestone
Time frame: Baseline
Clinical Characteristic: Number of Patients Categorized by Relevant Surgical History in Addition to Scoliosis Surgery Related to SMA Categorized by Type of Surgery
Time frame: Baseline
Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year
Time frame: Up to 12 months
Total Number of Scheduled and Unscheduled Healthcare Visits per Patient per Year
Time frame: Up to 12 months
Number of Scheduled and Unscheduled SMA-related Medical Visits
Time frame: Up to 12 months
Number of SMA-related Emergency Room Visits
Time frame: Up to 12 months
Number of SMA-related Hospitalizations
Time frame: Up to 12 months
Number of Patients Categorized by Reason for Hospitalization
Time frame: Up to 12 months
Number of Patients Categorized by Reason for Admission to Intensive Care Unit (ICU)
Time frame: Up to 12 months
Number of Patients With a Multidisciplinary Follow-up
Time frame: Up to 12 months
Number of Patients Categorized by Medical Areas Involved in Follow-up
Time frame: Up to 12 months
Number of Patients Categorized by Type of Additional Tests Needed
Time frame: Up to 12 months
Number of Times Each Additional Test Was Performed
Time frame: Up to 12 months
Total Additional Tests
Time frame: Up to 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Oct 2024.
Related trials for Spinal Muscular Atrophy Type I
RecruitingObservational study
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)
Spinal Muscle Atrophy
Not yet recruitingEarly Phase 1
SPX-01 Gene Therapy in Pediatric Patients With Spinal Muscular Atrophy Type 1 (RISE)
Spinal Muscular Atrophy (SMA)
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 1/2
A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I
Spinal Muscular Atrophy 1
Active, not recruitingPhase 3
Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi
Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Novartis Pharmaceuticals study director
Novartis Pharmaceuticals
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Spinal Muscular Atrophy Type I and Spinal Muscular Atrophy Type II, run by Novartis at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cost per Year of Use of Resources for Medical Visits (time frame: Up to 12 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Oct 2024.